Skip to main content
. 2019 Jun 5;76(9):893–903. doi: 10.1001/jamapsychiatry.2019.1189

Table 3. Most Frequently Reported Adverse Events in the Maintenance Phase in Patients Who Achieved Stable Remission and Those Who Achieved Stable Responsea.

Adverse Event No. (%) of Patients
Esketamine Nasal Spray and Oral Antidepressant (n = 152) Oral Antidepressant and Placebo Nasal Spray (n = 145)
Dysgeusia 41 (27.0) 10 (6.9)
Vertigo 38 (25.0) 8 (5.5)
Dissociation 35 (23.0) 0
Somnolence 32 (21.1) 3 (2.1)
Dizziness 31 (20.4) 7 (4.8)
Headache 27 (17.8) 14 (9.7)
Nausea 25 (16.4) 1 (0.7)
Vision blurred 24 (15.8) 1 (0.7)
Hypoesthesia oral 20 (13.2) 0
Anxiety 12 (7.9) 5 (3.4)
Nasal discomfort 11 (7.2) 4 (2.8)
Paresthesia 11 (7.2) 0
Viral upper respiratory tract infection 11 (7.2) 12 (8.3)
Blood pressure increased 10 (6.6) 5 (3.4)
Dizziness postural 10 (6.6) 3 (2.1)
Sedation 10 (6.6) 1 (0.7)
Vomiting 10 (6.6) 1 (0.7)
Confusional state 9 (5.9) 0
Diplopia 9 (5.9) 0
Hypoesthesia 9 (5.9) 0
Paresthesia oral 8 (5.3) 1 (0.7)
Throat irritation 8 (5.3) 1 (0.7)
a

Adverse events are listed in decreasing order based on incidence within the esketamine plus antidepressant group and in alphabetical order for events with the same incidence. The incidence was 5% or greater in either treatment group.